Despite promising clinical evidence, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing significant difficulty from PBMs. Such organizations are frequently building obstacles to access, including steep price restrictions and approval processes that hinder user access. Market believe that th